SmallCapPodcast.com
AGORACOM Small Cap TV AGORACOM Small-Cap Gold and Resources TV Chinese Small Cap Stock TV
LISTEN NOW LISTEN NOW LISTEN NOW
Mar 22, 2021 | by admin | Permalink

Agoracom interviews CEOs of small cap companies.

In this episode of the Small Cap CEO Interviews podcast, AGORACOM speaks with Novamind (CSE:NM) CEO and Director, Yaron Conforti.

Last week Novamind announced that its wholly-owned subsidiary, Cedar Clinical Research has been selected as a key research site for a clinical trial focused on treatment-resistant depression by Merck & Co., a world-leading pharmaceutical company.
The phase II study will assess the efficacy and safety of a new Merck drug for treatment-resistant depression (TRD), a mental health condition that affects approximately 30% of people who suffer from major depressive disorder.
Yaron Conforti, CEO and Director of Novamind said: “Under Dr. Robison’s leadership, Cedar Clinical Research has proven itself as a best-in-class research site for emerging mental health therapeutics. We’re excited to work with Merck, a world-class pharmaceutical company, to advance research for innovative mental health treatments.”

Sit back, relax and watch this powerful interview with Yaron Conforti, CEO and Director of Novamind.

Download This Episode

View Company Website

Visit Investor Relations Hub